Bone Marrow Cells Show Promise in Helping the Pancreas Repair Itself

Type 1 diabetes develops when the immune system attacks the insulin-producing beta cells in the pancreas. For decades, researchers assumed these cells were permanently lost. But a striking observation has shifted that thinking: some people who have lived with Type 1 diabetes for 50 years or more still produce small amounts of c-peptide—a marker that their remaining beta cells are functioning.

This discovery opened a crucial question: if beta cells can survive that long, could they potentially be regenerated or expanded? The answer may lie in a type of immune cell called multipotent stromal cells, or MSCs.

MSCs are cells isolated from bone marrow that have two key properties: they can reduce harmful immune responses (immunomodulation) and they secrete compounds that promote tissue repair and growth (pro-regenerative activity). Because of these properties, scientists have long been interested in using MSCs to treat damaged tissues throughout the body.

In diabetes research, the focus is on whether MSCs can help repair the pancreatic islets—the clusters of cells that house beta cells and regulate blood sugar.

In animal models of diabetes, MSC transplantation has shown promising results. Studies demonstrate that these cells can reduce high blood sugar levels and support the repair of islets. Based on this encouraging evidence, MSC treatment is now being tested in clinical trials with human patients.

These early-stage studies represent a shift from insulin replacement toward regenerative medicine—an approach aimed at helping the body repair its own insulin-producing machinery.

While researchers have a good understanding of how MSCs dampen immune responses, they don't yet fully understand how they trigger beta cell regeneration. The leading hypothesis is that MSCs send signals to resident progenitor or precursor cells already present in the pancreas, encouraging them to mature into functional beta cells.

A separate, decades-long scientific debate persists about where regenerated adult beta cells actually come from—whether they arise from existing beta cells dividing, from precursor cells maturing, or from other sources. Resolving this question is essential for optimizing MSC-based therapies.

Understanding these mechanisms is an active area of research and will likely be crucial as trials expand and scientists work to improve treatment effectiveness.

Source: Cells. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.